Salix Pharmaceuticals: Ensuring Continuity of Care in Hepatic Encephalopathy

Monday, September 30
7:00 – 7:45 am
Location: Mandalay Bay Ballroom A

Speakers

Marina Roytman, MD, FACP, FAASLD

Theater Information

This presentation will take attendees through current trends in chronic liver disease and cirrhosis, such as mortality and hospitalizations, and provide an overview of hepatic encephalopathy, including clinical manifestations and the role of gut-derived neurotoxins. Recognizing gaps in care, guideline adherence and adoption, and the risk of recurrence will also be discussed. Efficacy and safety data for a treatment option will be reviewed in the context of the case study.

Supported by Salix Pharmaceuticals